FLOMENBERG NEAL (Chief Scientific Officer) sold 5.2% of their position (211.91K shares) of TEVOGEN BIO HOLDINGS INC. on the open market
Open‑market sale worth $231.7K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 3 sales
Filed: 3/11/2025ACC: 0001062993-25-005198
Officer· Chief Scientific Officer
Since Feb 2024
-211.91K
Net shares
Net seller
$231.7K
Total sold
3
Open market trades
0B · 3S
3
Total transactions
211.91K disposed
Non-Derivative Transactions3
Common Stock
Direct
Shares
−71.27K
Price / share
$1.14
Trade value
$81.25K
% of position
1.8%
3/7/2025
4.04M→3.97M
Common Stock
Direct
Shares
−70.38K
Price / share
$1.09
Trade value
$76.72K
% of position
1.8%
3/10/2025
3.97M→3.90M
Common Stock
Direct
Shares
−70.25K
Price / share
$1.05
Trade value
$73.76K
% of position
1.8%
3/11/2025
3.90M→3.83M
Total
Net shares
−211.91K
Net value
-$231.73K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 3/7/2025 | S · Sale | −71.27K | $1.14 | $81.25K | 1.8% | 4.04M | 3.97M |
| Common Stock Direct | 3/10/2025 | S · Sale | −70.38K | $1.09 | $76.72K | 1.8% | 3.97M | 3.90M |
| Common Stock Direct | 3/11/2025 | S · Sale | −70.25K | $1.05 | $73.76K | 1.8% | 3.90M | 3.83M |
| Total | −211.91K | -$231.73K | ||||||
Derivative Transactions0
No derivative transactions reported